Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023

Rhea-AI Summary

Beyond Air, Inc. (NASDAQ: XAIR) announced that its CEO, Steve Lisi, will participate in two investor conferences in March 2023. The first event is the 35th Annual Roth Conference from March 12-14, where Lisi will engage in a fireside chat on March 13 in Laguna Niguel, CA. The second event is the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, featuring a presentation by Lisi on March 15 at 9:20 AM ET in a virtual format. Beyond Air focuses on developing inhaled nitric oxide treatments for respiratory conditions and is advancing its LungFit systems in clinical trials for severe lung infections.

GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in two upcoming investor conferences in March 2023.

35th Annual Roth Conference – March 12-14, 2023
	Format:		Fireside Chat
	Date:		Monday, March 13, 2023
	Participant:		Steve Lisi, Chairman & CEO, Beyond Air
	Location:		Laguna Niguel, CA

Oppenheimer 33rd Annual Healthcare Conference – March 13-15, 2023
	Format:		Presentation
	Date & Time:		Wednesday, March 15, 2023, at 9:20-9:50 AM ET
	Participant:		Steve Lisi, Chairman & CEO, Beyond Air
	Location:		Virtual presentation
	Webcast Link:		Click Here

Please contact your representative at either Roth or Oppenheimer to schedule a one-on-one meeting with Beyond Air during the respective conference.

About Beyond Air^®, Inc.
Beyond Air is a medical device and biopharmaceutical company dedicated to harnessing the power of nitric oxide through its revolutionary NO Generator and Delivery System, LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company has received FDA approval for its first system, LungFit PH for persistent pulmonary hypertension of the newborn. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), nontuberculous mycobacteria (NTM) and severe lung infections in other settings. Additionally, Beyond Cancer, an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

Forward Looking Statements
This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: Beyond Cancer’s ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials concerning the ultra-high concentration nitric oxide product candidate; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for the ultra-high concentration nitric oxide product candidate; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; Beyond Cancer’s ability to fund and the results of further pre-clinical studies and clinical trials of the ultra-high concentration nitric oxide product candidate; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Cancer and Beyond Air undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS
Investor Relations Contacts

Edward Barger
Head of Investor Relations
ebarger@beyondair.net

Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com

Media Contact

Kori-Ann Taylor
Head of Marketing
ktaylor@beyondair.net

FAQ

What is the date of the 35th Annual Roth Conference where XAIR will be presenting?

The 35th Annual Roth Conference will take place from March 12-14, 2023, with Beyond Air's CEO participating on March 13.

When will Beyond Air present at the Oppenheimer 33rd Annual Healthcare Conference?

Beyond Air will present at the Oppenheimer 33rd Annual Healthcare Conference on March 15, 2023, from 9:20 to 9:50 AM ET.

Who is representing Beyond Air at the investor conferences in March 2023?

Steve Lisi, the Chairman and CEO of Beyond Air, will represent the company at both investor conferences.

What is the focus of Beyond Air's research and development?

Beyond Air focuses on developing inhaled nitric oxide for respiratory conditions and ultra-high concentration nitric oxide for treating solid tumors.

Where can I find more information about Beyond Air's conference presentations?

More information about Beyond Air's conference presentations can be found on their official website or by contacting their investor relations.